Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery Incubator Award.
After experiencing partnering success and a $315 million deal with Japan-based Astellas Pharma Inc. for their LAMP-Vax platform technology in allergy, Immunomic Therapeutics, in concert with BioHealth Innovation, is giving back to the region’s growing scientific community with the Cancer Discovery Incubator Award. The incubator will enable and accelerate beginning ventures aimed at offering measurable change in oncological healt
{iframe}http://www.businesswire.com/news/home/20161108005137/en/Immunomic-Therapeutics-Maryland-Biotech-Community{/iframe}